Danon disease is a rare, multisystemic genetic disorder with X-linked inheritance, caused by pathogenic or likely pathogenic variants of the LAMP2 gene, which encodes lysosome-associated membrane protein 2. The central biological consequence is defective lysosomal function and impaired autophagic flux, with intracellular accumulation of autophagic vacuoles, glycogen, altered sarcoplasmic material and damaged mitochondria. The heart is the prognostically dominant organ: the disease often manifests with severe hypertrophic cardiomyopathy, ventricular pre-excitation, conduction disturbances, ventricular arrhythmias, progression to heart failure and need for heart transplantation at a young age, especially in males.
The classic clinical triad includes cardiomyopathy, skeletal myopathy and cognitive or neuropsychological deficit, but this triad is not always complete and should not be required in order to suspect the diagnosis. In males, the phenotype is usually early and severe, with onset in childhood or adolescence; in females, the presentation is often later and more variable because of X-chromosome inactivation, but it can still become severe, with hypertrophic or dilated cardiomyopathy, arrhythmias and heart failure. In addition to the heart, skeletal muscle and nervous system, the retina, liver, respiratory system, gastrointestinal system and neuropsychiatric sphere may be involved.
The true prevalence is not defined, because the disease is rare, many cases are recognized only after genetic testing and some patients have historically been classified as having sarcomeric hypertrophic cardiomyopathy, idiopathic dilated cardiomyopathy, isolated Wolff-Parkinson-White syndrome or unspecified myopathy. The use of genetic panels in pediatric cardiomyopathies has shown that LAMP2 variants can account for a clinically relevant proportion of severe early-onset left ventricular hypertrophy, especially when pre-excitation, increased creatine kinase, elevated transaminases with preserved liver function, muscle weakness, pigmentary retinopathy or a family history compatible with X-linked transmission coexist.
Danon disease belongs to the group of non-sarcomeric genetic cardiomyopathies with a hypertrophic, dilated or evolving phenotype. Its identification is particularly important because it can mimic common hypertrophic cardiomyopathy, but it has a different natural history, arrhythmic risk, extracardiac involvement, family implications and prognosis. In a child or adolescent, marked left ventricular hypertrophy associated with ventricular pre-excitation should immediately suggest metabolic, storage or lysosomal disorders, including Danon disease, PRKAG2, Pompe disease, Anderson-Fabry disease and some mitochondrial diseases.
The typical cardiac phenotype in males is a concentric or asymmetric hypertrophic cardiomyopathy, often severe and rapidly progressive. Wall thickness may increase substantially already in pediatric age, while the electrocardiogram may show high voltages, deep Q waves, repolarization abnormalities, ventricular pre-excitation and a short PR interval. Pre-excitation may be interpreted as Wolff-Parkinson-White syndrome, but in the context of Danon disease it should not be considered an isolated electrical problem: it signals a diffuse cellular disease of the myocardium and is associated with a risk of tachyarrhythmias, heart failure and sudden death.
In females, the presentation is more variable. Some carriers develop left ventricular hypertrophy, others dilated cardiomyopathy, and others a mixed or progressive phenotype. Onset may occur in adolescence, young adulthood or later; severity partly depends on the pattern of X-chromosome inactivation in tissues, which can determine functional mosaicism. This explains why two women with the same variant may have very different manifestations, and why an apparently paucisymptomatic woman may transmit the variant to severely affected male children.
The rarity of the disease makes it difficult to estimate prevalence in the general population. Pediatric hypertrophic cardiomyopathy series indicate that LAMP2 can be identified in a small but clinically relevant percentage of patients with unexplained hypertrophy, especially when the phenotype is not purely sarcomeric. The disease is probably underdiagnosed in adults with dilated cardiomyopathy, in women with apparently idiopathic heart failure and in patients with pigmentary retinopathy or hypercreatine kinasemia not investigated from a cardiological perspective.
Danon disease is not only a cardiomyopathy. Skeletal myopathy may be mild, proximal and slowly progressive, or recognizable only through increased creatine kinase. Cognitive deficit can range from learning difficulties to more evident intellectual disability, especially in males. Pigmentary retinopathy, often peripheral and with a “salt and pepper” pattern, may be asymptomatic in the initial stages or cause reduced vision, visual field abnormalities, macular involvement and cone-rod dystrophy. Retinal involvement is important because it may precede the cardiological diagnosis or identify female carriers.
The disease was initially described as a lysosomal glycogen storage disease with normal acid alpha-glucosidase activity. This historical distinction remains clinically useful: in Pompe disease, the defect is enzymatic, involves acid alpha-glucosidase and is treatable with enzyme replacement therapy; in Danon disease, acid alpha-glucosidase activity is normal and the problem involves the LAMP2 protein, with alteration of lysosomal trafficking and function. Confusing the two conditions means making errors in diagnosis, prognosis, genetic counseling and treatment.
The natural history is severe. In males, the disease may progress to advanced heart failure, ventricular arrhythmias and heart transplantation already in the second or third decade of life. In females, average progression is later, but not necessarily benign; some develop advanced heart failure, arrhythmias and need for transplantation. Mortality is often related to heart failure, sudden death or arrhythmic complications. For this reason, early suspicion is decisive: diagnosis when the patient is already in the terminal stage reduces the margin for family surveillance, arrhythmic prevention and transplantation planning.
The established etiological cause of Danon disease is a pathogenic or likely pathogenic variant of the LAMP2 gene, located on the X chromosome. The gene encodes different isoforms of the LAMP2 protein, including LAMP2A, LAMP2B and LAMP2C; the LAMP2B isoform is particularly relevant for cardiac and skeletal muscle. Variants may be nonsense, frameshift, splice-site, deletions, duplications or missense, and many cause complete loss or marked reduction of the protein. The consequence is an X-linked dominant disorder: hemizygous males, having only one X chromosome, tend to manifest earlier and more severe forms; heterozygous females show phenotypic variability related to mosaicism from X-chromosome inactivation.
The LAMP2 protein is a component of the lysosomal membrane and participates in maintaining lysosomal integrity, fusion between autophagosomes and lysosomes, degradation of intracellular material and regulation of autophagy. In the cardiomyocyte, a cell with high energy demand and limited regenerative capacity, the autophagy-lysosome system is essential for removing damaged proteins, dysfunctional organelles and altered mitochondria. When LAMP2 is absent or defective, the autophagosome is not correctly processed in the lysosome; the material to be degraded accumulates; the cell progressively becomes filled with autophagic vacuoles and undegraded residues.
Cellular damage is not a simple inert deposit. Vacuolar accumulation alters sarcomeric architecture, interferes with contraction, modifies intracellular trafficking, compromises mitochondrial quality and activates oxidative stress. Mitophagy, the selective removal of damaged mitochondria, becomes ineffective; this results in dysfunctional mitochondria, inadequate energy production, increased reactive oxygen species and vulnerability to cell death. The cardiomyocyte initially attempts to compensate through hypertrophy, but this adaptive response progressively becomes maladaptive, with increased ventricular mass, diastolic stiffness, fibrosis and electrical instability.
Danon hypertrophic cardiomyopathy therefore arises from a subcellular defect different from that of classic sarcomeric cardiomyopathies. In sarcomeric forms, the primary problem involves contractile proteins, calcium sensitivity, contraction energetics and myofibrillar organization; in Danon disease, the primary problem is lysosomal-autophagic. This explains why the phenotype may be hypertrophic but accompanied by extracardiac clues, pre-excitation, increased creatine kinase, histological vacuolization and rapid progression toward systolic failure. Hypertrophy is not a simple response to load, but an expression of metabolic-cellular disease.
Myocardial fibrosis appears with progression. Cardiomyocyte death, oxidative stress, fibroblast activation and interstitial remodeling produce fibrous replacement and alteration of electrical conduction. Fibrosis increases ventricular stiffness, worsens diastolic relaxation, favors the transition from a hypertrophic phenotype to a dilated phenotype and creates a substrate for ventricular tachycardias. Cardiac magnetic resonance imaging may show late gadolinium enhancement, often extensive in advanced stages, which signals fibrotic expansion and irreversible myocardial damage.
Ventricular pre-excitation in Danon disease is frequent and may depend on atrioventricular accessory pathways or diffuse abnormalities of myocardial conduction in a metabolically abnormal heart. The electrocardiographic pattern with short PR interval and widened QRS complexes or delta waves may lead to a diagnosis of Wolff-Parkinson-White syndrome. However, the clinical significance is broader: in an adolescent with ventricular hypertrophy, pre-excitation and elevated creatine kinase, the hypothesis of a storage disease must precede the label of isolated sarcomeric hypertrophic cardiomyopathy.
Skeletal myopathy shares the same mechanism as cardiac involvement. Muscle fibers accumulate autophagic vacuoles, glycogen and undegraded material, with myofibrillar disorganization and possible proximal weakness. In males, creatine kinase is often significantly increased; in females, it may be normal or mildly elevated. Transaminases may be high without true hepatic failure, because alanine aminotransferase and aspartate aminotransferase may also reflect muscle damage. This finding is clinically important: an adolescent with “high transaminases” and a hypertrophic heart should not be investigated only as a hepatology patient.
Neurocognitive and retinal involvement results from the systemic expression of LAMP2 and the vulnerability of tissues with high metabolic activity. Cognitive deficit in males may already be evident at school age; in females it is more variable. The retina may develop alterations of the retinal pigment epithelium, peripheral pigmentary dystrophy, macular involvement and photoreceptor dysfunction. Since retinopathy may be minimally symptomatic, ophthalmological assessment should not wait for the onset of important visual disturbances.
The final pathophysiology of the heart combines hypertrophy, diastolic dysfunction, electrical instability, fibrosis, progressive systolic dysfunction and heart failure. At first, increased wall thickness reduces ventricular compliance and increases filling pressures; later, fibrosis and loss of cardiomyocytes reduce contractile function; in advanced stages, the ventricle may dilate and the ejection fraction falls. Output becomes insufficient, pulmonary or systemic congestion, arrhythmias, syncope and need for advanced therapies appear. The rapidity of this sequence, especially in males, makes Danon disease one of the most aggressive genetic cardiomyopathies.
Clinical assessment must begin with the history, including cardiological, neuromuscular, cognitive, ophthalmological and family history. In males, onset often occurs in childhood or adolescence with fatigue, exertional dyspnea, palpitations, chest pain, syncope, reduced sports performance or incidental detection of a murmur, cardiomegaly, left ventricular hypertrophy or pre-excitation on the electrocardiogram. In some cases, the first event is severe, such as ventricular tachyarrhythmia, acute heart failure or sudden death. The disease may therefore be recognized too late if hypertrophy is interpreted as an athletic variant, non-syndromic sarcomeric hypertrophy or isolated Wolff-Parkinson-White syndrome.
The clinical interview should look for signs linking the heart and skeletal muscle. The patient may report difficulty climbing stairs, getting up from the floor, running, sustaining prolonged physical activity or lifting weights; weakness is often proximal and may be underestimated because cardiomyopathy dominates the picture. Some patients do not report evident weakness but present with elevated creatine kinase, persistently high transaminases or a history of inconclusive hepatological investigations. In children, parents and teachers should be asked about exercise tolerance, motor skills, learning, attention and school development.
The neurocognitive history is essential. Learning difficulties, cognitive delay, neuropsychological disorders or need for school support are frequent in males; in females these aspects may be mild or absent, but they should not be excluded without assessment. The presence of mood disorders, anxiety, adjustment difficulties or neuropsychiatric symptoms may complicate the management of a severe and progressive cardiac disease. The patient and family must be assessed in a non-stigmatizing way, distinguishing cognitive deficit, psychological burden of the diagnosis and consequences of chronic heart failure.
The ophthalmological history should include night vision difficulties, reduced peripheral visual field, photophobia, visual decline, myopia, diagnosis of pigmentary retinopathy or unexplained retinal abnormalities. Retinopathy may initially be asymptomatic, especially if peripheral, but fundus examination, optical coherence tomography, fundus autofluorescence and electroretinography can identify abnormalities before the patient perceives a deficit. Pigmentary retinopathy in a subject with hypertrophic cardiomyopathy or an X-linked family history should raise consideration of LAMP2.
Family history must be reconstructed carefully over at least three generations. Young male deaths, heart transplantation, hypertrophic cardiomyopathy, dilated cardiomyopathy, sudden death, Wolff-Parkinson-White syndrome, implantable defibrillator, pacemaker, “high transaminases”, myopathy, school difficulties and retinopathy should be sought. The X-linked pattern may emerge from affected males through the maternal line, carrier mothers with later-onset disease and absence of male-to-male transmission. However, de novo variants and germline mosaicism may make the family history apparently negative.
On cardiological physical examination, there may be a systolic murmur from mitral regurgitation or dynamic obstruction, fourth heart sound, signs of congestion, pulmonary crackles, edema, hepatomegaly, jugular venous distension or peripheral hypoperfusion in advanced stages. Left ventricular outflow tract obstruction may occur in some patients, but it is not mandatory and should not guide diagnostic reasoning on its own. Blood pressure may be normal; bradycardia, tachycardia or rhythm irregularity must be correlated with electrocardiogram and prolonged monitoring.
Neuromuscular examination may show proximal weakness, difficulty with postural transitions, reduced endurance, mild hypotonia, reduced reflexes or nonspecific signs. Danon myopathy does not always produce a striking neurological phenotype, especially in females; for this reason, the absence of weakness does not exclude the diagnosis. The heart is frequently much more compromised than skeletal muscle. This imbalance is an important diagnostic point: a lysosomal disease may be mainly cardiac while still having altered muscle markers.
In females, presentation requires particular caution. A young or adult woman with non-ischemic dilated cardiomyopathy, ventricular arrhythmias, pre-excitation, family history of severely affected males or retinopathy may have Danon disease even without evident myopathy. Some women present with severe and progressive cardiomyopathy, while others remain asymptomatic for years. Variability should not lead to minimization of risk: a carrier must be considered a potentially affected patient and should be followed with cardiological, genetic and, when indicated, ophthalmological and neuromuscular surveillance.
Diagnostic suspicion arises from the association between early-onset cardiomyopathy, severe left ventricular hypertrophy or unexplained dilated cardiomyopathy, pre-excitation or other electrical disturbances, increased creatine kinase, elevated transaminases with preserved liver function, skeletal myopathy, cognitive deficit, pigmentary retinopathy and family history compatible with X-linked transmission. The pathway must be rapid because the disease can progress within a short time toward advanced heart failure and malignant arrhythmias.
The 12-lead electrocardiogram is often highly informative. It may show ventricular pre-excitation, short PR interval, delta waves, widened QRS complexes, increased voltages, deep Q waves, repolarization abnormalities, bundle branch blocks, supraventricular tachycardias or signs of myocardial damage. An electrocardiogram with severe hypertrophy and pre-excitation in an adolescent should shift the reasoning from common sarcomeric hypertrophic cardiomyopathy toward a metabolic or storage disease. Holter monitoring and, in selected cases, prolonged recorders are used to identify nonsustained ventricular tachycardias, pauses, atrial tachyarrhythmias, ectopic burden and correlation with syncope or palpitations.
Transthoracic echocardiography defines morphology and function. In males, marked left ventricular hypertrophy is often observed, sometimes concentric, with possible right ventricular hypertrophy, atrial dilation, diastolic dysfunction, dynamic obstruction in some cases, mitral regurgitation and progressive reduction in systolic function. In females, the picture may be hypertrophic, dilated or mixed. Echocardiography must measure wall thicknesses, volumes, ejection fraction, global longitudinal strain, right ventricular function, dynamic gradients, valves and pulmonary pressures. Strain may be abnormal even when the ejection fraction still appears preserved.
Cardiac magnetic resonance imaging is fundamental for defining ventricular mass, distribution of hypertrophy, biventricular function, fibrosis and tissue damage. Late gadolinium enhancement may be extensive and progressive, with prognostic and arrhythmic significance. T1 mapping and extracellular volume may contribute to characterization, but they do not replace genetics. Magnetic resonance imaging also helps differentiate Danon disease from sarcomeric hypertrophic cardiomyopathy, amyloidosis, Anderson-Fabry disease, Pompe disease, mitochondrial diseases and other phenocopies. When magnetic resonance imaging is not possible, serial echocardiography and selected computed tomography may provide structural information, but tissue characterization remains less complete.
Blood chemistry tests should include creatine kinase, lactate dehydrogenase, aspartate aminotransferase, alanine aminotransferase, bilirubin, gamma-glutamyltransferase, alkaline phosphatase, albumin, coagulation, creatinine, electrolytes, high-sensitivity troponin, B-type natriuretic peptide or N-terminal pro-B-type natriuretic peptide. Increased creatine kinase supports muscle involvement; increased transaminases with preserved hepatic synthetic function may reflect muscle origin; natriuretic peptides and troponin document cardiac stress and damage. Acid alpha-glucosidase activity must be assessed when the picture may simulate Pompe disease.
There is no universally accepted official clinical system for diagnosing Danon disease based only on signs and symptoms. According to GeneReviews, specialist reviews and contemporary cardiology consensus, the diagnosis is made by integrating a suggestive phenotype with molecular or protein confirmation. In operational terms, it is necessary to:
Genetic testing is therefore the decisive examination. It may be performed as a cardiomyopathy panel, a panel for hypertrophic cardiomyopathies and phenocopies, clinical exome sequencing or targeted LAMP2 analysis when suspicion is strong. Interpretation must distinguish pathogenic, likely pathogenic, uncertain significance, likely benign and benign variants. A variant of uncertain significance is not sufficient to confirm the diagnosis and should not be used alone for predictive family testing; it requires correlation with phenotype, segregation, functional data, periodic review and genetic counseling.
Skeletal muscle biopsy or endomyocardial biopsy is not always necessary today if genetics is conclusive, but it may be useful in doubtful cases, variants not clearly classifiable or suspicion of another disease. Histologically, autophagic vacuoles with sarcolemmal features, glycogen accumulation, lysosomal abnormalities, myofibrillar disorganization and reduction or absence of LAMP2 on immunohistochemistry or immunoblot are observed. Cardiac biopsy is more invasive and should be reserved for situations in which the result changes the diagnosis or management. Skeletal muscle biopsy may be less risky, but may not fully represent the cardiac phenotype.
Extracardiac assessment must be systematic. Neurological and neuromuscular examination defines strength, endurance, respiratory function and motor limitations. Neuropsychological assessment documents learning, executive functions, adaptation and need for support. Ophthalmological examination should include fundus examination, optical coherence tomography, autofluorescence, visual field testing and electroretinography when indicated. Spirometry and respiratory assessment are useful especially in patients with myopathy or advanced heart failure. The goal is not to multiply examinations without purpose, but to build a multisystemic picture useful for prognosis, treatment and follow-up.
The differential diagnosis is broad. PRKAG2 causes hypertrophy, pre-excitation and glycogen accumulation, but does not have the same lysosomal defect and follows autosomal dominant genetics. Pompe disease may cause hypertrophic cardiomyopathy and myopathy, but acid alpha-glucosidase activity is reduced and enzyme replacement therapy exists. Anderson-Fabry disease may produce hypertrophy, arrhythmias, proteinuria, neuropathy and cutaneous changes, with signs of glycosphingolipid storage. Mitochondrial diseases may associate cardiomyopathy, myopathy, lactic acidosis, deafness, diabetes or multisystemic neurological disease. Sarcomeric hypertrophic cardiomyopathy remains possible, but is less likely when pre-excitation, elevated creatine kinase, cognitive deficit and retinopathy coexist.
The treatment of Danon disease is currently centered on specialist cardiological management, arrhythmic prevention, treatment of heart failure, multisystemic surveillance, genetic counseling and early evaluation for heart transplantation in patients with progression. In ordinary clinical practice, there is no established etiological therapy capable of stably restoring LAMP2 function. Gene therapy with an adeno-associated viral vector serotype 9 containing LAMP2B is experimental and should not be presented as standard treatment.
The management of heart failure follows the general principles of cardiomyopathies, but must be adapted to the phenotype. In hypertrophic phases with preserved systolic function, the goal is to control symptoms, congestion, heart rate, dynamic obstruction if present and arrhythmias, avoiding excessive preload reduction in a stiff ventricle. When the disease evolves toward systolic dysfunction, recommended therapies for heart failure with reduced ejection fraction are applied if tolerated, taking into account blood pressure, renal function, potassium, risk of bradycardia and arrhythmias. Response may be limited because the primary defect remains cellular and progressive.
Arrhythmic surveillance must be aggressive and continuous. Electrocardiogram, periodic Holter monitoring, prolonged monitoring, syncope assessment and selected electrophysiological study are important tools. Pre-excitation may require electrophysiological assessment and ablation when high-risk accessory pathways or documented tachyarrhythmias exist, but ablation does not modify the underlying cardiomyopathy. An implantable defibrillator must be considered based on ventricular function, ventricular tachycardias, syncope, extent of fibrosis, family history, speed of progression and recommendations for genetic cardiomyopathies. The decision is complex because arrhythmic risk may be high even at a young age.
Heart transplantation is a central component of prognosis in patients with advanced disease. In males with rapid progression, reduced ejection fraction, refractory heart failure, malignant arrhythmias or functional worsening, referral to a transplant center should not be delayed. Waiting until the stage of multiorgan failure reduces the chances of success. Post-transplant outcomes reported in the literature are generally acceptable and the disease does not recur in the transplanted heart because the new organ has normal LAMP2, although extracardiac manifestations and problems related to immunosuppression remain.
Neuromuscular management is supportive but not secondary. Physiotherapy, strength assessment, prevention of muscle mass loss, respiratory function monitoring, fatigue management and adaptation of physical activity must be personalized. Intense competitive physical activity is generally problematic in patients with severe cardiomyopathy, marked hypertrophy, arrhythmias or a defibrillator; light or rehabilitative exercise may be useful if defined by the cardiologist and physiatrist. Skeletal myopathy may be less evident than the cardiac problem, but it affects autonomy, quality of life and recovery after transplantation.
Ophthalmological assessment must be scheduled even in the absence of symptoms. Fundus examination, optical coherence tomography, autofluorescence and functional tests can document pigmentary retinopathy and macular involvement. Recognition of retinal abnormalities is useful for visual management, for school or work adaptation and for identifying affected relatives. Retinopathy usually does not guide vital prognosis as the heart does, but it may become a relevant source of disability.
Genetic counseling is mandatory. After identification of the familial variant, targeted testing should be proposed to relatives at risk, along with cardiological surveillance of carriers and reproductive discussion. Heterozygous women should not be considered simple healthy carriers: they may develop severe cardiomyopathy and transmit the variant to their children. Affected males transmit the X chromosome to all daughters and to no sons; heterozygous females have, at each pregnancy, a 50% probability of transmitting the variant. Counseling must also include de novo variants, mosaicism and interpretive limits of variants of uncertain significance.
Cardiological follow-up must be close and adapted to severity. In patients diagnosed in pediatric age or adolescence, serial controls with echocardiogram, electrocardiogram, Holter monitoring, natriuretic peptides, troponin, cardiac magnetic resonance imaging when indicated and functional assessment are necessary. In patients with rapid progression, arrhythmias or systolic dysfunction, the interval between controls must be shortened and an advanced cardiomyopathy and heart failure center must be involved. Follow-up must also include school, development, psychological support, rehabilitation and family.
Gene therapy is a rational prospect because the disease derives from loss of function of a single gene. Studies with an adeno-associated viral vector serotype 9 directed to LAMP2B have shown initial biological and clinical signals, but the strategy remains experimental and carries immunological, hepatic, systemic and safety risks that require evaluation in controlled studies. After serious adverse events and regulatory changes in 2025, the clinical message must remain cautious: gene therapy does not replace early diagnosis, arrhythmic surveillance, heart failure treatment and transplantation assessment.
Prognosis depends on biological sex, age at onset, severity of hypertrophy, ventricular function, fibrosis, arrhythmias, pre-excitation, speed of progression, access to transplantation, genetic variant and quality of follow-up. In males, the disease is often very aggressive, with major cardiac events at a young age; in females, the average course is later but not benign. Early diagnosis improves the possibility of arrhythmic protection, transplantation planning, family screening and multidisciplinary management, but it does not eliminate the biological severity of the disease.
The most important complications are cardiac. Heart failure may begin with diastolic dysfunction from ventricular hypertrophy, exertional dyspnea, exercise intolerance and increased filling pressures; with progression, fibrosis, cardiomyocyte loss, ventricular dilation, reduced ejection fraction, pulmonary congestion, systemic congestion, functional mitral regurgitation and low output appear. This transition from the hypertrophic phenotype to the dilated or hypokinetic phenotype is one of the most unfavorable prognostic moments.
Arrhythmias represent a relevant cause of morbidity and mortality. Pre-excitation may favor supraventricular tachycardias; myocardial fibrosis and cellular damage create a substrate for ventricular tachycardia; atrial dilation favors atrial fibrillation and flutter; conduction disturbances may cause bradycardia, syncope or need for pacing. Sudden death may occur even in young patients and must be prevented with risk stratification, serial monitoring and timely indication for a defibrillator when appropriate.
Syncope is both a complication and a warning sign. It may derive from ventricular tachyarrhythmias, rapid supraventricular tachycardias, high-conduction pre-excitation, bradyarrhythmias, dynamic obstruction, low output or hypotension. In a patient with Danon disease, it should not be interpreted as a benign event without complete cardiological evaluation. The presence of syncope modifies risk stratification and may accelerate decisions on monitoring, defibrillator, antiarrhythmic therapy or referral to an advanced center.
Thromboembolic events may occur in the presence of atrial fibrillation, atrial dilation, systolic dysfunction, intracavitary thrombi or low output. Ischemic stroke, systemic embolism and intracardiac thrombosis become more likely in dilated or arrhythmic phases. Prevention requires recognition of atrial arrhythmias, echocardiographic assessment, anticoagulation when indicated and attention to periods of acute heart failure or immobilization.
Progression to advanced heart failure entails multiorgan complications. Reduced perfusion and venous congestion may produce renal failure, hyponatremia, congestive hepatopathy, malnutrition, sarcopenia, intolerance to therapy and repeated hospitalizations. These complications are not only terminal consequences: they can make transplantation more difficult if they are not recognized and treated early. For this reason, late referral to a transplant center is a frequent and dangerous error.
Neuromuscular complications include proximal weakness, reduced endurance, motor difficulties, respiratory function abnormalities and limitation of autonomy. Skeletal myopathy may worsen with heart failure, sedentary behavior, malnutrition and hospitalizations. In patients undergoing transplantation, preoperative muscle condition influences rehabilitation, functional recovery and quality of life. Management that is only cardiological, without neuromuscular assessment, is incomplete.
Ocular complications derive from retinopathy. Peripheral pigmentary changes may remain silent, but macular involvement, cone-rod dystrophy, macular atrophy or cystoid macular edema may reduce vision. Visual loss has an impact on school, work, driving, autonomy and quality of life. Ophthalmological surveillance makes it possible to recognize progression, correct visual deficits, plan support and identify relatives who present retinal manifestations before cardiac ones.
Cognitive, psychological and social complications are particularly relevant in children and adolescents. Learning difficulties, intellectual disability, anxiety, isolation, sports limitations, implanted devices, the prospect of transplantation and familial risk create a high burden. Management requires neuropsychological, school and family support. Cognitive deficit should not be confused with poor cooperation; on the contrary, it should guide clear communication methods, adapted therapeutic education and caregiver involvement.
Family complications concern missed diagnoses, transmission of the variant and delayed screening. A mother with mild or undiagnosed cardiomyopathy may have a severely affected male child; an apparently healthy sister may develop disease years later; a variant of uncertain significance may generate incorrect interpretations if it is not reassessed. Prevention of family complications depends on correct genetic counseling, targeted testing, longitudinal surveillance and accurate communication of risk.
Finally, there are complications related to underdiagnosis. Labeling Danon disease as common sarcomeric hypertrophic cardiomyopathy may delay recognition of multisystemic risk; treating pre-excitation as the only problem may ignore progressive cardiomyopathy; attributing elevated creatine kinase and transaminases to isolated causes may miss the unity of the syndrome. The most serious diagnostic complication is therefore fragmentation of the picture: heart, muscle, retina and cognition must be read as manifestations of the same lysosomal defect.